N-myc gene amplification and/or loss of heterozygosity of chromosome 1 (LOH lp) are important criteria for prognosis and progression in human neuroblastoma (NB). Despite the high incidence of alterations of the p53 gene in human cancers, very few p53 mutations have been reported in NB. The objective of our study was to search for p53 mutations in NB and their correlation with N-myc amplification and clinical or pathologic parameters. We analyzed 14 selected cases of NB from the Spanish Protocol N-II-92. We found a missense mutation in codon 248 CGG to GGG (Arg/Gly) in one case of stage 4 NB with no N-myc amplification. Our results confirm the low incidence of p53 gene mutation in neuroblastoma and the absence of correlation with histopathologic parameters.
1. Nakagawara A, Arima M, Azar C, Scavarda N, Brodeur G. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res52:1364-1368, 1992
2.
2. Schleirmacher G, Peter M, Michon J, Hugot JP, Vielh P, Zucker JM, Magdelénat H, Thomas G, Delaterre O. Two distinct deleted regions on the short arm of chromosome I in neuroblastoma. Genes Chromosom Cancer10:275-281, 1994
3.
3. Mejia C, Navarro S, Pellin A, Castel V, Llombart Bosch A. Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res18 (A):801-806, 1998
4.
4. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumor types. Nature342: 705-708, 1989
5.
5. Pellin A, Boix-Ferrero J, Carpio D, López-Terrada D, Carda C, Navarro S, Peydro-OlayaA, Triche TJ, Llombart-Bosch A. Molecular alterations of the RB1, TP53 and MDM2 genes in primary and xenografted human osteosarcomas. Diag Mol Pathol6:333-341, 1997
6.
6. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res52:2243-2247, 1992
7.
7. Biegel JA, Burk CD, Barr FG, Emanuel BS. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res52:3391-3395, 1992
8.
8. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whong-Peng J. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest89:640-647, 1992
9.
9. Manhani R, Cristofani LM, Filho VO, Bendit I. Concomitant p53 mutation and MYCN amplification in neuroblastoma. Med Pediatr Oncol29:206-207, 1997
10.
10. Castel V, Garcia-Miguel P, Melero C, Navajas A, Navarro S, Molina J, Badal MD, Ruiz-Jimenez JI on behalf of the Spanish Neuroblastoma Study Group. The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies. Eur J Cancer4:642-645, 1995
11.
11. Brodeur JM, Seeger RC, Barret A. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol6:1874-1881, 1988
12.
12. Shimada H, Chatten J, Newton WA, Sachs N, Hamoud AB, Chiba T, Marsden HB, Misugi K. Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Can Inst73:405-405, 1984
13.
13. Sambrook J, Fritsch EF, Maniatis T. Analysis of genomic DNA by Southern hybridization. In Nolan C, Ford N, Ferguson M (eds). Molecular cloning: a laboratory manual. Cold Spring Harbor, Lab Press, New York, p 931-931, 1989
14.
14. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics5:874-879, 1989
15.
15. Crabbe DCG, Peters J, Seeger RC. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Pathol1: 229-234, 1992
16.
16. Cattoretti G, Pileri S, Parraviccini C, Becker M, Poggi S, Biulco C, Key G, D'Amato L, Sabattini E, Feudale E, Reynolds F, Gerde J, Rilke F. Antigen unmasked on formalin-fixed, paraffin-embedded tissue sections. J Pathol171:83-98, 1993
17.
17. Bratthauer G, Adams L. Immunohistochemistry: Antigen detection in tissue. In Mikel U (ed). Advanced laboratory methods in histology and pathology. Armed Forces Institute of Pathology, Washington, DC, pp 3-40, 1994
18.
18. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hoving E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: Update compilation. Nucl Acids Res24: 141-146, 1996
19.
19. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human neuroblastoma and neuroepithelioma-derived cell lines. Oncogene7:127-133, 1992
20.
20. Imamura J, Bartram CR, Berthold F, Harms D, Haruhiko N, Koeffler P. Mutation of the p53 gene in neuroblastoma and its relation with N-myc amplification. Cancer Res53:4053-4058, 1993
21.
21. Hosoi G, Hara J, Okamura T, Osugi Y, Ishihara S, Fukuzawa M, Okada S, Tawa A. Low frequency of the p53 gene mutations in neuroblastoma. Cancer73:3087-3093, 1994
22.
22. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gross P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res53:5269-5273, 1993
23.
23. Mazars GR, Jeanteur P, Lynch HT, Lenoir G, Theillet C. Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene. Oncogene7:781-782, 1992
24.
24. Cho Y, Svetlana G, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science265:346-355, 1994
25.
25. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential acompany loss of wild-type p53. Cell70:923-935, 1992
26.
26. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell70:937-948, 1992
27.
27. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med329:1318-1327, 1993
28.
28. Levine AJ. The p53 tumor-suppressor gene. N Engi J Med326:1350-1352, 1992
29.
29. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res52:674-677, 1992
30.
30. Ohgaki H, Eibi RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihaus P. p53 mutations in nonastrocytic human brain tumors. Cancer Res51:6202-6205,1992
32. Spruck CH, Tsai YC, Huang DP, Yang AS, Rideout WM, Gonzalez ZuluetaM, Choi P, Lo KW, Yu MC, Jones PA. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res52:4787-4790, 1992
33.
33. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J, Goss PE. Mutations of the p53 gene do not occur in testis cancer. Cancer Res53:3574-3578, 1993
